EGFR and non-small cell lung carcinoma: Although the results of this analysis should be considered with care given the small sample size, we note that the latter figure is consistent with the time to clinical progression of 8–12 months observed in multiple studies of unselected patients with EGFR mutant NSCLC treated with first-line erlotinib therapy, including one study which used the same clinical cohort at the same institution (23).